ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO438

What New Guideline Brought to Turkish Hypertension Profile?

Session Information

Category: Hypertension and CVD

  • 1401 Hypertension and CVD: Epidemiology, Risk Factors, and Prevention

Authors

  • Deger, Serpil muge, Yuksek ihtisas University Faculty of Medicine, ANKARA, Turkey
  • Derici, Ulver, Gazi University Faculty of Medicine, ANKARA, Turkey
  • Sindel, Sukru, Gazi University Faculty of Medicine, ANKARA, Turkey
  • Sengul, Sule, Ankara University School of Medicine, Ankara, Turkey
  • Akpolat, Mehmet Tekin, Liv Hospital ULUS-ISTANBUL, ISTANBUL, Turkey
  • Erdem, Yunus, Hacettepe University Faculty of Medicine, ANKARA, Turkey
  • Arici, Mustafa, Hacettepe University Medical Faculty, Sihhiye-Ankara, Turkey
  • Karatan, Oktay, Ankara University School of Medicine, Ankara, Turkey
  • Turgan, Cetin, Hacettepe University Faculty of Medicine, ANKARA, Turkey
  • Hasanoglu, Enver, Gazi University Faculty of Medicine, ANKARA, Turkey
  • Erturk, Sehsuvar, Ankara University School of Medicine, Ankara, Turkey
  • Caglar, Sali, Hacettepe University Faculty of Medicine, ANKARA, Turkey
Background

2017 ACC/AHA guideline lowered the numbers for the diagnosis of HT to 130/80 mmHg for adult population with the aim for the early diagnosis of life threatening complications of HT such as heart attack and/ or stroke. Turkey is a developing Euroasian country with the population of 82 million and has dominance of relatively younger age.Although, young population is predominating, cardiovascular disease is still major public health concern in Turkey. In 2003, the first large sample sized (n=4910) epidemiological study (PatenT study) showed the prevalence of HT as 31.8% in Turkey. After nine years, PatenT 2 trial showed prevalence of hypertension as 30.3 %.This study aimed to determine to assess current epidemiology of hypertension including, prevalence, awareness and control rates among Turkish adults, using criteria from the 2017 ACC/AHA guideline and the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC7).

Methods

We analyzed data from PatenT 2 study (n= 5437). Blood pressure measurements were performed three times and awareness and treatment were assessed by self-reporting and control was defined as SBP/DBP less than 140/90 mmHg.

Results

According to the 2017 ACC/AHA and JNC7 guidelines, the crude prevalence of hypertension among Turkish adults was 48.4% and 30.3%, respectively and the awareness rate of the hypertension diagnosis was 34.2 % and 54.7 %, respectively. The control rate in hypertensives was 28.7 % according to the JNC 7, 17.9 % according to the 2017 ACC/AHA guideline.

Conclusion

Compared with the JNC7 guideline, the 2017 ACC/ AHA guideline results in a considerable increase in the prevalence of hypertension and substantial decrease in control rates and awareness of hypertension in Turkish adults.

Funding

  • Private Foundation Support